Drug Profile
Anti-CD19 chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics
Alternative Names: ICTCAR003Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Innovative Cellular Therapeutics
- Developer Innovative Cellular Therapeutics; Zhejiang University
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II B-cell lymphoma; Non-Hodgkin's lymphoma
- No development reported Diffuse large B cell lymphoma; Follicular lymphoma; Leukaemia; Lymphoid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma in China (Parenteral)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Follicular lymphoma(Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)